Genentech Buys Regor’s CDK Inhibitors for $850 Million

Genentech acquired Cambridge, MA-based Regor Therapeutics Group’s portfolio of CDK inhibitors for $850 million in cash. The most promising drug candidate included in the deal is RGT-419B, a next-generation CDK4 inhibitor that showed signs of single agent efficacy in a phase Ia dose escalation study in patients with HR-positive, HER2-negative advanced breast cancer. Under the terms of the deal, Regor will oversee two ongoing phase I trials of RGT-419B until completion, after which Genentech will manage clinical development, manufacturing, and commercialization of the candidate.